Introduction
Influenza causes a major burden on primary and secondary care services and families every winter in temperate countries. [1] [2] [3] Although influenza rarely results in secondary bacterial infection 4 it is linked with excess antibiotic prescribing in children. 5 The symptoms of influenza are diffuse 6 and may be difficult to distinguish from bacterial infections, 7 particularly in primary care where the majority of influenza cases present, but diagnostic sampling is not widely available. Overuse of antibiotics is a major public health challenge due to increased antibiotic resistance. 8 It is therefore of interest to determine the role of influenza immunization programmes in reducing antibiotic prescribing. 9 Two clinical trials have examined the effect of influenza vaccination on antibiotic prescribing: one of live attenuated influenza vaccine (LAIV) in adults, 10 the other of inactivated influenza vaccine (IIV) in children aged 6 months to 9 years. 11 The size of the effect in the paediatric trial was one less antibiotic prescription per child per season. Both these studies are now over 15 years old and antibiotic prescribing practices have changed over time.
A new policy of offering annual vaccination with intranasal LAIV to all children aged 2-16 years in the UK began in September 2013. 12 In 2015/16, between 34% and 57% (varying by UK country) of preschool children aged 2 to 4 years were vaccinated in primary care. 13, 14 V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Whether LAIV reduces antibiotic prescribing is of interest to clinicians, parents and policy makers evaluating the impact of the new influenza vaccination programme. There are no trials of the effect of LAIV on antibiotic prescribing in children, and further trials are unethical in the UK owing to the recommendation to vaccinate all children. Observational studies comparing vaccinated and unvaccinated children lead to confounding by indication, since both influenza vaccination and complications are more common in children with chronic conditions. 14, 15 We evaluated the effectiveness of LAIV in reducing antibiotic prescribing in preschool children in primary care in the UK. We focused on the prescribing of amoxicillin, indicated for two common complications of influenza: community-acquired pneumonia and (in some children) acute otitis media. We used a large primary care database and applied the self-controlled case series (SCCS) methodology 16, 17 to minimize confounding by indication.
Methods

Ethics
All data in this study were anonymized. Data collection has been approved by the South East NHS Multicentre Research Ethics Committee. The analyses presented here were approved by the Scientific Review Committee of the data providers (QuintilesIMS), study reference number SRC 14-004.
Study design: the self-controlled case series method
This method was originally developed to examine vaccine safety but has now been applied in a range of pharmacoepidemiological studies, including for evaluating the effect of influenza vaccination on asthma 18, 19 and COPD exacerbations. 20 The method includes only individuals who have had the outcome of interest (cases), and compares the incidence rate within each case of the outcome of interest during a time-limited exposed period (e.g. the period of vaccine protection) with rates during unexposed, or 'baseline' periods. Thus, the question is 'when' rather than 'who' regarding the experience of events. Since the analyses are conditional on each case, any characteristics such as gender or prevalence of chronic conditions that do not vary during the study period are inherently controlled for. 17 Any time-varying factors, like age or seasonal variation need to be adjusted for in the analyses.
Data source
We used The Health Improvement Network (THIN) primary care database for this study.
21 THIN contains anonymized longitudinal data on diagnoses, prescriptions, vaccinations and demographic information for around 6% of the UK population. THIN is approximately representative of the general UK population in terms of demographic characteristics, and primary care practices contributing to THIN are representative of all UK general practices in terms of prescribing and consultation rates. 22, 23 Influenza vaccination uptake rates in THIN, including those of LAIV, have been found to be similar to uptake figures published by UK public health agencies. 24, 25 Data are entered by the general practitioner (GP, primary care clinician) during patient consultations. Prescriptions are recorded in THIN using drug codes that map to the British National Formulary. 26 27 Children were considered eligible for inclusion in one or both study cohorts if they were registered with a THIN practice on 1 September 2013 or 2014, met the age criteria for the target group to receive LAIV in primary care in that respective season (children aged 2 to 3 years inclusive on 31 August 2013 for 2013/14 and children aged 2 to 4 years inclusive on 31 August 2014 in 2014/15) and had at least one amoxicillin prescription during either of the two study periods. That is, children were included in the analysis for 2013/14 if they had at least one amoxicillin prescription in 2013/14; and in the analysis for 2014/15 if they had at least one amoxicillin prescription in 2014/15.
Study period and population
Children were followed up from the start to the end of the study period or until they deregistered from the practice. Infections leading to a prescription of amoxicillin are likely to cluster within families. In order to ensure independence of outcomes we randomly selected one child per family (identified via the family number in THIN 24 ) in the eligible age range for inclusion in the cohort. 24 We included both vaccinated and unvaccinated cases. Since estimation of the relative risk of amoxicillin prescribing is among children only, unvaccinated children do not contribute to the estimation of the vaccine effect (only to estimation of the other time-varying covariates in the model). The vaccinated periods are long in relation to the observation period (see below). It would be impossible to distinguish between seasonal variation and vaccine effects during periods when almost all cases have been vaccinated (as would happen during early spring). Therefore including unexposed (i.e. unvaccinated) cases makes it possible to more accurately adjust for seasonal effects. 17 
Outcome
The outcome in this study was amoxicillin prescriptions. Amoxicillin is indicated for community-acquired pneumonia and acute otitis media in children who are systemically unwell, at high risk of complications, or experiencing persisting symptoms. Petersen et al. 28 found that only 50%-60% of antibiotic prescriptions had an associated indication recorded on the same day. Therefore we considered any prescription for amoxicillin irrespective of the indication. A child may receive more than one amoxicillin prescription each season. One of the assumptions of the SCCS method is that outcomes are independent, conditional on the time-varying covariates. 16, 17 In order to meet this assumption we created prescribing episodes and assumed that all amoxicillin prescriptions in a 30 day period were associated with the same infection. Separate prescription episodes were assumed to be independent of each other. Only the first prescription in each 30 day period was included.
Influenza vaccination status
The exposure variable was receipt of LAIV. We used a code list developed for a previous study to identify children who have been vaccinated using LAIV and their date of vaccination each season. 24 Children with severe immunosuppression, asthma or active wheezing are recommended to receive IIV rather than LAIV. Children receiving at least one dose of IIV were excluded from the analyses for a particular season. Children who are not in a clinical risk group (94.5% of preschool children 24 ) are recommended to receive one dose of LAIV. We therefore did not have a sufficient number of cases to examine the effectiveness of two versus one dose of LAIV. Children who had received two doses of vaccine were included in the study, but only the effect of one dose was assessed; that is, we did not further split the Hardelid et al.
exposure period into sub-periods following the first dose and the second dose.
LAIV vaccination status was treated as a time-varying covariate. The vaccination exposure periods are summarized in Figure S1 (available as Supplementary data at JAC Online). There is little evidence regarding how long influenza vaccine immunity lasts in children. [29] [30] [31] We assumed that vaccine-induced immunity lasts for 6 months in our baseline scenario, then varied assumptions about vaccine protection in sensitivity analyses.
Parents of children who required amoxicillin are likely to delay vaccination until symptoms have improved. In order for the SCCS model to be valid, the outcome of interest should not influence the exposure (LAIV receipt). Therefore, we included a 'pre-vaccination' period in the analyses, lasting from the day of vaccination #14 to the day of vaccination #1. We assumed that vaccine-induced immunity begins at 14 days after vaccination, in line with previous studies. [31] [32] [33] We therefore excluded a 14 day period after the date of vaccination. Excluding the immediate 14 day post-vaccination period also allowed us to take into account that amoxicillin prescription rates are likely to remain low immediately after vaccination, since children should be in good health at the time of vaccination.
Seasonality and influenza circulation periods
A number of different virus infections, including influenza, lead to amoxicillin prescribing in children during winter seasons. To allow for underlying seasonality of amoxicillin prescriptions (whatever the causative pathogen), we split the follow-up time into weeks of the winter season, and adjusted for week as a factor variable in the statistical models. By using this approach, we assumed that the underlying seasonality (i.e. timing) of respiratory virus circulation (including influenza) is the same among vaccinated and unvaccinated children. In terms of vaccine effects, the SCCS model tests whether the relative incidence is lower in vaccinated versus unvaccinated periods, adjusted for underlying seasonality of amoxicillin prescribing.
Since we hypothesized that LAIV would only be effective in preventing amoxicillin prescribing during periods when influenza virus was circulating in the community, we further split the follow-up time into influenza circulating and non-circulating periods and included this variable as a timevarying covariate in the SCCS model. In the 2013/14 season, influenza circulated between end of December 2013 (week 52) and end of March (week 14) according to sentinel swabbing schemes run by Public Health England (PHE). 34 In 2014/15, influenza circulation was established by week from the beginning of December (week 49) and continued until the beginning of April (week 15). 27 
Statistical analyses
Only children who had had at least one amoxicillin prescription were included in the analyses. We describe their characteristics in terms of age at cohort inception, sex, influenza vaccination status and whether they were in a clinical risk group owing to underlying chronic conditions, and therefore considered to be at increased risk of influenza-related complications, in each season. We used a code list used by PHE to measure vaccination uptake in primary care to define whether a child was in a clinical risk group. 35 A child was classified as being in a clinical risk group if they had any relevant code recorded up to one year before the start of each winter season.
We plotted the proportion of cases who had been vaccinated and the number of prescriptions each week to assess the overlap in timing between exposure and outcome events. The SCCS models were fitted using a conditional Poisson regression model. Vaccine effectiveness (VE) was estimated as
in which the IRR is the relative rate ratio of amoxicillin prescribing in vaccinated periods, relative to unvaccinated periods, estimated by the fully adjusted SCCS model. Statistically significant VE in preventing amoxicillin prescriptions was defined as a Wald test P value ,0.05. Separate models were fitted for each of the two seasons. We adjusted for single years of age (2, 3, 4 and 5 years) as a categorical variable, and active influenza circulation and week number as time-varying covariates.
We conducted sensitivity analyses to determine the impact of changing assumptions about the effect of age and the duration of vaccination protection on VE estimates: (i) restricting analyses to the period of active influenza circulation only (scenario 1); (ii) increasing the number of age groups to 6 month age groups rather than single years of age (scenario 2); (iii) assuming vaccine protection lasts for 9 months (scenario 3; this means that vaccine protection extends beyond the end of the study period in this scenario); and (iv) splitting the 6 month vaccinated period into two subperiods from 14 days to less than 3 months and 3 months to less than 6 months after vaccination (scenario 4).
Absolute risk differences cannot be obtained using SCCS. We conducted a simple calculation (not allowing for herd immunity) to examine the impact of increasing LAIV uptake in 2-to 4-year-old children in England beyond current levels, given our estimated VE. First, we obtained the current number of amoxicillin prescriptions in England by estimating the amoxicillin prescribing rate in 2-to 4-year-old children in English THIN practices between September 2014 and April 2015, and applying these rates to mid-year population estimates from the Office for National Statistics. 36 Second, by assuming a constant ratio between VE and uptake, with VE set at the estimated value for the 2014/15 season, we calculated the expected number of amoxicillin prescriptions (Prescriptions exp ) for a given scenario of vaccination uptake (VU S ) as: ) and VE is the vaccine effectiveness estimated from our study for 2014/15 (see Text S1).
We used Stata 13 38 for data management and model fitting and R 3.3.1 for graphical output.
Results
We identified 90 788 children aged 2 to 3 years in 2013 and 142 273 children aged 2 to 4 years in 2014 (Figure 1 ). There were 33 137 children from 378 general practices who had at least one amoxicillin prescription during either of the two seasons. Of these children, 14 368 (43.4%) had received at least one dose of LAIV in either of the two seasons. Overall, 5071 children (15.3%) contributed person time to both study periods. The characteristics of the children in each cohort are shown in Table 1 . The vast majority of children in either cohort had only one prescription episode each season.
Half of the vaccines had been administered by the beginning of November in both seasons (Figure 2 ). Amoxicillin prescriptions displayed several peaks, one in the beginning of December, followed by two more peaks in mid-February and mid-March. The amoxicillin prescribing rate was lower in the 14 days before and the 14 days after vaccination among the vaccinated cases in both seasons ( Figure S2 ).
Influenza vaccination was associated with a significant decrease in amoxicillin prescriptions in both winter seasons. LAIV VE in preventing amoxicillin prescriptions was 12.8% in 2013/14 and 14.5% in 2014/15 ( Table 2) . Overlapping 95% confidence intervals from the two seasons suggest a similar effect size.
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Including the indicator of influenza circulation had negligible effect on influenza VE estimates in either season.
Subdividing the age groups had negligible effect, whereas restricting the study period to weeks with active influenza circulation led to a reduction in the number of cases included in the model and greater variability in the VE estimates. When vaccine protection was assumed to be 9 instead of 6 months, VE estimates increased in both seasons. When we split the vaccinated period into two sub-periods, VE point estimates were similar across the two shorter periods. The CIs for the VE estimates from all sensitivity analyses overlapped with those for the baseline scenario for both seasons.
We estimate that 626 932 amoxicillin prescriptions were issued to 2-to 4-year-old children in England between September 2014 and April 2015. Assuming a VE of 14.5%, only 591 868 amoxicillin prescriptions would have been prescribed in this season had vaccine uptake been 50% in 2-to 4-year-olds ( Figure S3 ) rather than the observed uptake of 37.6%. This amounts to a decrease of 35 064 prescriptions or 5.6%.
Discussion
We found a 12.8% to 14.5% reduced rate of amoxicillin prescribing during periods of LAIV-induced immunity in preschool children. The effectiveness of LAIV in preventing amoxicillin prescribing episodes was robust to assumptions about the duration of LAIV protection and age effects. Children with ≥1 amoxicillin prescription in study period n =22665 Figure 1 . Flowchart of the final selection of cases included in the SCCS analysis. IIV, inactivated influenza vaccine. Data shown are n (%), unless otherwise specified.
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The study included over 30 000 children during the first two seasons of the universal paediatric influenza vaccination programme in the UK. Only a small proportion of amoxicillin prescriptions are likely to be prescribed owing to influenza complications, and hence any effect of influenza vaccination is likely to be small. Therefore, a large study is required to detect a vaccination effect. The large number of cases also allowed us to finely adjust for the seasonal pattern of amoxicillin prescribing using week of the winter season. Number of amoxicillin prescription episodes Figure 2 . Cumulative proportion of cases in each cohort vaccinated and the number of amoxicillin prescriptions, by week of the study period. The striped area shows the period of active influenza circulation, and the asterisk indicates the peak week of influenza circulation according to PHE sentinel swabbing schemes. 27, 34 Influenza vaccine for prevention of amoxicillin prescribing
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We used the SCCS method to estimate relative amoxicillin prescribing rates during vaccinated and unvaccinated periods for each child. This is the first time, to our knowledge, that SCCS has been used to estimate influenza VE in children. Use of the SCCS method means any confounding by indication, which often arises in cohort studies of influenza VE, 39 is implicitly controlled for. We could not examine the effect on prescriptions prescribed for particular symptoms. However, we were still able to detect a significantly reduced risk of amoxicillin prescribing during periods of LAIV-induced immunity. Since such a small proportion of children received two doses of LAIV, we examined effectiveness after only one dose. However, these results are relevant to the vast majority of children in the UK who are only recommended to receive one LAIV dose.
One alternative explanation for our result is that GPs are less likely to prescribe antibiotics to children who have been vaccinated, if they consider these children to be at lower risk of influenza complications. However, GPs are advised to decide on antibiotic prescribing based only on the severity and longevity of symptoms and the presence of chronic conditions, not on whether the infection is caused by a particular pathogen. 40 We therefore consider it unlikely that decisions regarding antibiotic prescriptions are based on a child's vaccination status.
Three aspects of our study results were unexpected. First, the effect sizes were similar in the two seasons under study, despite varying degrees of matching between the circulating and vaccine strains of influenza. We note that significant VE in preventing laboratory-confirmed influenza was still reported by PHE in 2014/15.
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Rather than simply reducing the incidence of influenza-related complications leading GPs to prescribe amoxicillin, LAIV may lead to non-specific protection against respiratory infections. Large, randomized clinical trials of LAIV in young children, with antibiotic prescribing as an outcome, are required to address this question.
Second, when we increased the assumed period of LAIVinduced immunity to 9 months, the point estimate of LAIV VE increased. If protection persists beyond 6 months, inclusion of the 6-9 month period in the reference category of the base scenario will have caused the effect to be underestimated. When the assumed period of LAIV immunity is 9 months, the immunity period extends to the end of observation and the analysis relies heavily on non-vaccinated cases to estimate the weekly seasonal effects. However, there is no reason why seasonal effects should differ between vaccinated and unvaccinated cases.
Third, we hypothesized that the VE estimate would be highest during the months immediately following vaccination. Amoxicillin prescribing is a non-influenza-specific outcome. The seasonal pattern of overall amoxicillin prescribing is not in alignment with that of influenza, whereas the seasonal pattern of prescribing attributable to influenza should be (with some lag). The burden due to influenza cannot be deciphered from the data and no method can disentangle the effect of waning vaccine immunity from the effect of other circulating viruses leading to amoxicillin prescriptions. Overall, our sensitivity analyses are useful in showing that effects beyond 6 months are protective, indicating that LAIV effectiveness is often long-lasting throughout the season.
Further, we found that restricting the observation period to weeks of active influenza circulation led to highly variable estimates of the VE. Restricting the study period leads to a reduction in statistical power through three mechanisms. First, it reduces the number of cases included in the model, as highlighted in the footnote to Table 2 . Second, restricting the study period will in this case mean that the ratio of exposed versus unexposed time is even larger, leading to a loss of efficiency. Third, restricting the study period will mean some vaccinated cases do not contribute any unexposed time to the model, so that the vaccine effects are estimated based on an even smaller number of children. Hence, restricting the study period led to much more variable estimates of VE and larger CIs, particularly for the 2013/14 season when the period of influenza circulation was shorter than in 2014/15. We note that the CIs for scenario 1 and the baseline scenario overlap in both seasons. In the absence of reliable data on the duration of LAIV-induced immunity among children, the size of the effect of LAIV on amoxicillin prescribing should therefore not be overestimated. Ongoing monitoring of the effect of LAIV on amoxicillin prescribing in preschool children is required.
Several other viruses, and in particular respiratory syncytial virus (RSV), is known to cause substantial morbidity in young children 41 and may lead to amoxicillin prescribing. RSV circulation in the UK peaks in early December. Since we adjust for week of the winter season, this should not bias our results, as long as the incidence of Hardelid et al.
RSV-related prescribing is the same in vaccinated and unvaccinated children. One small study has shown an increase in the risk of non-influenza respiratory viruses following IIV receipt, 42 but these results have not been replicated for LAIV. The risk of bias caused by differential timing of RSV circulation in relation to influenza vaccination is therefore likely to be minimal.
Our results add to a growing body of evidence showing a reduction in antibiotic prescribing associated with influenza vaccination. 43 Universal influenza vaccination of children could contribute to the effort to decrease antibiotic prescribing in primary care, where three quarters of antibiotics are prescribed in the UK. 44 Based on a simple calculation, we estimated that up to 5.6% of amoxicillin prescriptions could be prevented if LAIV uptake in 2-to 4-year-old children in England had been 50% rather than the observed 37.6%. More detailed studies are required to model the potential impact of increases in influenza vaccination uptake on antibiotic prescribing.
We found a significantly reduced risk of amoxicillin prescribing during periods of influenza vaccine immunity in preschool children vaccinated with LAIV. Influenza vaccination of children may lead to reductions in amoxicillin prescribing, but the effect may be small. Further efforts should be made to increase uptake of LAIV in preschool children under the universal influenza vaccination programme.
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